OSCR

Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1.

Overview

Authors: Diego Piqueras-Losilla1, Andrea Garcia-Rey1, Aline Huguet-Lachon2, Argimiro Mayoral-Olmos1, Isabel Campillo1, Melanie Nufer1, Mouli Chakraborty1, Ana Díaz-Maqueda1, Nuria Barquero1, Anchel Gonzalez-Barriga2, José Martinez-Hernandez3,4, María Gracia de Garnica García5, Geneviève Gourdon2, Ruben Artero6,7,8, Beatriz Llamusí1, Estefanía Cerro-Herreros1
ORCID iDs: Diego Piqueras-Losilla, José Martinez-Hernandez, Estefanía Cerro-Herreros
  1. ARTHEx Biotech. Parque Científico de la Universidad de Valencia, Calle del Catedrático Agustín Escardino Benlloch, 9, 46980 Paterna, Valencia, Spain
  2. Sorbonne Université, Inserm, Centre de Recherche en Myologie, Paris, France
  3. Fonds de Dotation Clinatec, Grenoble, France
  4. Grenoble Institute Neurosciences, Inserm, University Grenoble Alpes, Grenoble, France
  5. Micros Veterinaria S.L., León, Spain
  6. Human Translational Genomics. University Research Institute for Biotechnology and Biomedicine (BIOTECMED), Universidad de Valencia, Av. Dr. Moliner 50, 46100 Valencia, Spain
  7. INCLIVA Biomedical Research Institute, Av. Menéndez Pelayo 4 acc, 46010 Valencia, Spain
  8. CIBERER ISCIII, Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
Institutions: Universitat de València (Spain); Parc Científic de la Universitat de València (Spain); Inserm (France); Sorbonne Université (France); Centre de Recherche en Myologie; Grenoble Institute of Neurosciences (France); Fonds de Dotation Clinatec (France); Université Grenoble Alpes (France)
Journal: Cell reports. Medicine, volume 7, issue 8, article 102929
Dates: received 7 November 2025; accepted 24 June 2026; published online 22 July 2026; in print August 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1016/j.xcrm.2026.102929 · PMID 42486096 · PMCID PMC13522761 · OpenAlex W7170083443
Open access: gold, a free copy (OpenAlex)
Status: code on request
Categories: human (organism), mouse (organism), cellular / molecular (subfield)
Methods: Statistics, Physiology & signal measures
Keywords: myotonic dystrophy, antisense oligonucleotides, miR-23b, MBNL, alternative splicing, brain delivery, blood-brain barrier, CNS alterations, behavior correction, rare disease
MeSH: Brain*, MicroRNAs*, Myotonic Dystrophy*, Animals, Blood-Brain Barrier, Disease Models, Animal, DNA-Binding Proteins, Humans, Male, Mice, Mice, Transgenic, Myotonin-Protein Kinase, RNA-Binding Proteins (* major topic)
Topic: Genetic Neurodegenerative Diseases (Cellular and Molecular Neuroscience, Neuroscience), according to OpenAlex
Funding: “la Caixa” Foundation; Ministerio de Ciencia, Innovación y Universidades; Centro para el Desarrollo Tecnológico Industrial; Generalitat Valenciana; Instituto de Salud Carlos III; Agencia Valenciana de Innovación
Citations: not cited yet (Europe PMC); 90 references in the paper
Research resources: HRP-conjugated anti-GAPDH antibody RRID:AB_10847862, anti-MBNL1 antibody: for QDB assay RRID:AB_2140186, anti-NeuN antibody RRID:AB_2298772, RRID:AB_2340363, anti-MBNL1 monoclonal antibody RRID:AB_2618248, Anti-MBNL2 monoclonal antibody RRID:AB_2618250, RRID:AB_2633277, RRID:AB_2860576

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Code and data availability statement

The paper has a code and data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the data are available on request
  • it says that the code is available on request

Read it in the paper: doi.org/10.1016/j.xcrm.2026.102929.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Authors: added Diego Piqueras-Losilla (0009-0003-2667-234X); removed Diego Piqueras-Losilla
  • Funding: added “la Caixa” Foundation; Ministerio de Ciencia, Innovación y Universidades; Centro para el Desarrollo Tecnológico Industrial; Generalitat Valenciana; Instituto de Salud Carlos III; Agència Valenciana de la Innovació

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 16 authors, 10 keywords, 13 MeSH terms, 89 references, 8 RRIDs.

Cite

This paper

Piqueras-Losilla, D., Garcia-Rey, A., Huguet-Lachon, A., Mayoral-Olmos, A., Campillo, I., Nufer, M., Chakraborty, M., Díaz-Maqueda, A., Barquero, N., Gonzalez-Barriga, A., Martinez-Hernandez, J., de Garnica García, M. G., Gourdon, G., Artero, R., Llamusí, B., & Cerro-Herreros, E. (2026). Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1. Cell reports. Medicine, 7(8), 102929. https://doi.org/10.1016/j.xcrm.2026.102929

BibTeX

@article{piqueraslosilla2026fatty,
author = {Piqueras-Losilla, Diego and Garcia-Rey, Andrea and Huguet-Lachon, Aline and Mayoral-Olmos, Argimiro and Campillo, Isabel and Nufer, Melanie and Chakraborty, Mouli and Díaz-Maqueda, Ana and Barquero, Nuria and Gonzalez-Barriga, Anchel and Martinez-Hernandez, José and de Garnica García, María Gracia and Gourdon, Geneviève and Artero, Ruben and Llamusí, Beatriz and Cerro-Herreros, Estefanía},
title = {{Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1}},
journal = {Cell reports. Medicine},
year = {2026},
month = jul,
volume = {7},
number = {8},
pages = {102929},
publisher = {Elsevier},
issn = {2666-3791},
doi = {10.1016/j.xcrm.2026.102929},
url = {https://doi.org/10.1016/j.xcrm.2026.102929},
pmid = {42486096},
pmcid = {PMC13522761}
}

RIS

TY - JOUR
AU - Piqueras-Losilla, Diego
AU - Garcia-Rey, Andrea
AU - Huguet-Lachon, Aline
AU - Mayoral-Olmos, Argimiro
AU - Campillo, Isabel
AU - Nufer, Melanie
AU - Chakraborty, Mouli
AU - Díaz-Maqueda, Ana
AU - Barquero, Nuria
AU - Gonzalez-Barriga, Anchel
AU - Martinez-Hernandez, José
AU - de Garnica García, María Gracia
AU - Gourdon, Geneviève
AU - Artero, Ruben
AU - Llamusí, Beatriz
AU - Cerro-Herreros, Estefanía
TI - Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1
T2 - Cell reports. Medicine
J2 - Cell Rep Med
PY - 2026
DA - 2026/07/22
VL - 7
IS - 8
SP - 102929
SN - 2666-3791
PB - Elsevier
DO - 10.1016/j.xcrm.2026.102929
UR - https://doi.org/10.1016/j.xcrm.2026.102929
LA - en
ER -

CSL-JSON

{
"id": "10.1016/j.xcrm.2026.102929",
"type": "article-journal",
"title": "Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1",
"container-title": "Cell reports. Medicine",
"author": [
{
"family": "Piqueras-Losilla",
"given": "Diego"
},
{
"family": "Garcia-Rey",
"given": "Andrea"
},
{
"family": "Huguet-Lachon",
"given": "Aline"
},
{
"family": "Mayoral-Olmos",
"given": "Argimiro"
},
{
"family": "Campillo",
"given": "Isabel"
},
{
"family": "Nufer",
"given": "Melanie"
},
{
"family": "Chakraborty",
"given": "Mouli"
},
{
"family": "Díaz-Maqueda",
"given": "Ana"
},
{
"family": "Barquero",
"given": "Nuria"
},
{
"family": "Gonzalez-Barriga",
"given": "Anchel"
},
{
"family": "Martinez-Hernandez",
"given": "José"
},
{
"family": "de Garnica García",
"given": "María Gracia"
},
{
"family": "Gourdon",
"given": "Geneviève"
},
{
"family": "Artero",
"given": "Ruben"
},
{
"family": "Llamusí",
"given": "Beatriz"
},
{
"family": "Cerro-Herreros",
"given": "Estefanía"
}
],
"container-title-short": "Cell Rep Med",
"volume": "7",
"issue": "8",
"page": "102929",
"DOI": "10.1016/j.xcrm.2026.102929",
"PMID": "42486096",
"PMCID": "PMC13522761",
"ISSN": "2666-3791",
"publisher": "Elsevier",
"URL": "https://doi.org/10.1016/j.xcrm.2026.102929",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
22
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41598-026-54533-w
Hyperlipidemia induces hippocampal inflammation and loss of vascularity and can be rescued by silencing RIPK1.
Journal: Scientific reports
In common: mouse, cellular / molecular, 2 references
[2] doi:10.1126/scitranslmed.adq4529 [code]
Modulating alternative splicing of <i>MECP2</i> is a potential therapeutic strategy for Rett syndrome.
Journal: Science translational medicine
In common: mouse, 2 references
[3] doi:10.1093/nar/gkag287 [code]
Divalent siRNA for prion disease.
Journal: Nucleic acids research
In common: mouse, 2 references
[4] doi:10.1038/s41467-026-71432-w [code]
MeCP2 gene dosage-dependent neurodevelopmentally restricted defects arise by aberrant activation of cell fate-determining bivalent genes.
Journal: Nature communications
In common: mouse, cellular / molecular, 1 reference
[5] doi:10.1038/s41467-026-76725-8
TogoPhosTAC as a delivery-ready platform for targeted protein dephosphorylation.
Journal: Nature communications
In common: mouse, cellular / molecular, 1 reference
[6] doi:10.1038/s42003-026-09931-1
Elovanoid neuroprotection targets cell transcriptomics and proteomics to sustain synaptic integrity after brain injury.
Journal: Communications biology
In common: mouse, cellular / molecular, 1 reference
[7] doi:10.1002/advs.202514972
Neuid: A Novel Neuron-Enriched LncRNA that Connects Epigenetic Gene Silencing to Alzheimer's Disease.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
In common: mouse, cellular / molecular, 1 reference
[8] doi:10.1186/s10020-026-01471-y
Modest rescue of RBFOX1 splicing function attenuates Huntington's disease features.
Journal: Molecular medicine (Cambridge, Mass.)
In common: mouse, 1 reference
[9] doi:10.1371/journal.pcbi.1014422 [code]
Deciphering cell type-specific causal genetic effects on brain imaging-derived phenotypes and disorders with single-cell Mendelian randomization.
Journal: PLoS computational biology
In common: cellular / molecular, 1 reference
[10] doi:10.1038/s41586-026-10874-0 [code]
Amygdala astrocyte primary cilium mechanisms contribute to stress behaviours.
Journal: Nature
In common: mouse, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.